These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32750454)

  • 1. Secretion of the epithelial sodium channel chaperone PCSK9 from the cortical collecting duct links sodium retention with hypercholesterolemia in nephrotic syndrome.
    Molina-Jijon E; Gambut S; Macé C; Avila-Casado C; Clement LC
    Kidney Int; 2020 Dec; 98(6):1449-1460. PubMed ID: 32750454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.
    Haas ME; Levenson AE; Sun X; Liao WH; Rutkowski JM; de Ferranti SD; Schumacher VA; Scherer PE; Salant DJ; Biddinger SB
    Circulation; 2016 Jul; 134(1):61-72. PubMed ID: 27358438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney-derived PCSK9-a new driver of hyperlipidemia in nephrotic syndrome?
    Artunc F
    Kidney Int; 2020 Dec; 98(6):1393-1395. PubMed ID: 33276863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension.
    Berger JM; Vaillant N; Le May C; Calderon C; Brégeon J; Prieur X; Hadchouel J; Loirand G; Cariou B
    Atherosclerosis; 2015 Mar; 239(1):252-9. PubMed ID: 25621930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between plasma proprotein convertase subtilisin/kexin type 9 and blood lipids in patients with newly diagnosed primary nephrotic syndrome.
    Shen H; Feng S; Lu Y; Jiang L; Yang T; Wang Z
    Ren Fail; 2020 Nov; 42(1):405-412. PubMed ID: 32349585
    [No Abstract]   [Full Text] [Related]  

  • 7. [New insights into the pathophysiology of oedema in nephrotic syndrome].
    Rondon-Berrios H
    Nefrologia; 2011; 31(2):148-54. PubMed ID: 21461007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
    Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
    Liu S; Vaziri ND
    Nephrol Dial Transplant; 2014 Mar; 29(3):538-43. PubMed ID: 24166456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome.
    Larionov A; Dahlke E; Kunke M; Zanon Rodriguez L; Schiessl IM; Magnin JL; Kern U; Alli AA; Mollet G; Schilling O; Castrop H; Theilig F
    J Cell Mol Med; 2019 Oct; 23(10):6543-6553. PubMed ID: 31368174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
    Bohnert BN; Daiminger S; Wörn M; Sure F; Staudner T; Ilyaskin AV; Batbouta F; Janessa A; Schneider JC; Essigke D; Kanse S; Haerteis S; Korbmacher C; Artunc F
    Acta Physiol (Oxf); 2019 Dec; 227(4):e13286. PubMed ID: 31006168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome.
    Jatem E; Lima J; Montoro B; Torres-Bondia F; Segarra A
    Kidney Int Rep; 2021 Jan; 6(1):101-109. PubMed ID: 33426389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
    Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model.
    Carreras A; Pane LS; Nitsch R; Madeyski-Bengtson K; Porritt M; Akcakaya P; Taheri-Ghahfarokhi A; Ericson E; Bjursell M; Perez-Alcazar M; Seeliger F; Althage M; Knöll R; Hicks R; Mayr LM; Perkins R; Lindén D; Borén J; Bohlooly-Y M; Maresca M
    BMC Biol; 2019 Jan; 17(1):4. PubMed ID: 30646909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between circulating PCSK9 and proteinuria in nephrotic syndrome: A cross-sectional study.
    Doiron S; Paquette M; Baass A; Bollée G; Cardinal H; Bernard S
    Clin Biochem; 2022; 109-110():51-56. PubMed ID: 35940295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotic syndrome: PCSK9: a target for hypercholesterolaemia in nephrotic syndrome.
    Morris AW
    Nat Rev Nephrol; 2016 Sep; 12(9):510. PubMed ID: 27425160
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulation of epithelial sodium channel in puromycin aminonucleoside-induced unilateral experimental nephrotic syndrome in normal and analbuminemic Nagase rats.
    Yu Z; Schumacher M; Frey BM; Frey FJ; Vogt B
    Nephron Physiol; 2005; 101(3):p51-62. PubMed ID: 16020936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition.
    Kim HJ; Lee J; Chung MY; Hong S; Park JH; Lee SH; Park SW; Choi HK; Hwang JT
    Pharmacol Res; 2020 Nov; 161():105205. PubMed ID: 32998069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collecting duct (Na+/K+)-ATPase activity is correlated with urinary sodium excretion in rat nephrotic syndromes.
    Deschênes G; Doucet A
    J Am Soc Nephrol; 2000 Apr; 11(4):604-615. PubMed ID: 10752519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glomerulonephritis and sodium retention: enhancement of Na+/K+-ATPase activity in the collecting duct is shared by rats with puromycin induced nephrotic syndrome and mice with spontaneous lupus-like glomerulonephritis.
    Zolty E; Ibnou-Zekri N; Izui S; Féraille E; Favre H
    Nephrol Dial Transplant; 1999 Sep; 14(9):2192-5. PubMed ID: 10489230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.